References
- Aide N, Cappele O, Bottet P, et al (2003). Efficiency of [18F] FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging, 30, 1236-45. https://doi.org/10.1007/s00259-003-1211-4
- Ak I, Can C (2005). F-18 FDG PET in detecting renal cell carcinoma. Acta Radiol, 46, 895-9. https://doi.org/10.1080/02841850500335002
- Bachor R, Kotzerke J, Gottfried HW, et al (1996). Positron emission to-mography in diagnosis of renal cell carcinoma. Urologe A, 35, 146-50.
- Bertagna F, Motta F, Bertoli M, et al (2013). Role of F18-FDGPET/CT in restaging patients affected by renal carcinoma. Nucl Med Rev Cent East Eur, 16, 3-8. https://doi.org/10.5603/NMR.2013.0002
- Bomanji JB, Costa DC, Ell PJ (2001). Clinical role of positron emission tomography in oncology. Lancet Oncol, 2, 157-164. https://doi.org/10.1016/S1470-2045(00)00257-6
- Downey RJ, Akhurst T, Gonen M, et al (2004). Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol, 22, 3255-60. https://doi.org/10.1200/JCO.2004.11.109
- Ferlay J, Autier P, Boniol M, et al (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 18, 581-92.
- Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ (1997). FDG PET characterization of renal masses:preliminary experience. Clin Radiol, 52, 510-5. https://doi.org/10.1016/S0009-9260(97)80327-3
- Harada S, Sato S, Suziki E, et al (2011). The Usefulness of Pre-Radiofrequency Ablation SUVmax in 18F-FDG PET/CT to Predict the Risk of a Local Recurrence of Malignant Lung Tumors after Lung Radiofrequency Ablation. Acta Med Okayama, 65, 395-402.
- Horner MJ, Ries LAG, Krapcho M, et al (2010). SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute.
- Israel GM, Bosniak MA (2008). Pitfalls in renal mass evaluation and how to avoid them. Radiographics, 28, 1325-38. https://doi.org/10.1148/rg.285075744
- Jayson M, Sanders H (1998). Increased incidence of serendipitously discovered renal cell carcinoma. Urology, 51, 203-5. https://doi.org/10.1016/S0090-4295(97)00506-2
- Kang DE, White RL, Jr., Zuger JH, Sasser HC, Teigland CM (2004). Clinical use of fluorode-oxyglucose F-18 positron emission tomography for detection of renal cell carcinoma. J Urol, 171, 1806-9. https://doi.org/10.1097/01.ju.0000120241.50061.e4
- Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK (2012). Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun, 33, 967-73. https://doi.org/10.1097/MNM.0b013e3283561837
- Kocher F, Geimmel S, Hauptmann R, Reske SN (1994). Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med, 35, 223.
- Kumar R, Chauhan A, Lakhani P, et al (2005). 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses. Mol Imaging Biol, 7, 431-9. https://doi.org/10.1007/s11307-005-0026-z
- Lee YY, Choi CH, Kim CJ, et al (2009). The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for eary cervical cancer: Preliminary results. Gynecol Oncol, 115, 65-68. https://doi.org/10.1016/j.ygyno.2009.06.022
- Liu NB, Zhu L, Li MH, et al (2013). Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis. Asian Pac J Cancer Prev, 14, 3647-52. https://doi.org/10.7314/APJCP.2013.14.6.3647
- Luciani LG, Cestari R, Tallarigo C (2000). Incidental renal cell carcinoma: age and stage characterization and clinical implications, study of 1092 patients (1982-1997). Urology, 56, 58-62. https://doi.org/10.1016/S0090-4295(00)00534-3
- Ma JB, Chen EC, Song YP, et al (2013). Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (PET)-based parameters in neoadjuvant chemoradiation treatment of esophageal carcinoma. Asian Pac J Cancer Prev, 14, 2477-81. https://doi.org/10.7314/APJCP.2013.14.4.2477
- Majhail NS, Urbain JL, Albani JM, et al (2003). F-18 fluorodeoxyglucose positron emission Tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol, 21, 3995-4000. https://doi.org/10.1200/JCO.2003.04.073
- Martinez de Llano SR, Delgado-Bolton RC, Jimenez-Vicioso A, et al (2007). Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma. Rev Esp Med Nucl, 26, 19-29. https://doi.org/10.1157/13097378
- Miyakita H, Tokunaga M, Onda H, et al (2002). Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol, 9, 15-8. https://doi.org/10.1046/j.1442-2042.2002.00416.x
- Miyauchi T, Brown RS, Grossman HB, Wojno K, Wahl RL (1996). Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. J Nucl Med, 37, 64.
- Montravers F, Grahek D, Kerrou K, et al (2000). Evaluation of FDG up-take by renal malignancies (primary tumor or metastases) us-ing a coincidence detection gamma camera. J Nucl Med, 41, 78-84.
- Motzer RJ, Bander NH, Nanus DM (1996). Renal-cell carcinoma. N Engl J Med, 335, 865-75. https://doi.org/10.1056/NEJM199609193351207
- Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K (2009). The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol, 79, 29-35.
- Nakhoda Z, Torigian DA, Saboury B, Hofheinz F, Alavi A (2013). Assessment of the diagnostic performance of 18F-FDG-PET/CT for detection and characterization of solid renal malignancies. Hell J Nucl Med, 16, 19-24.
- Namura K, Minamimoto R, Yao M, et al (2010). Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-Dglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer, 10, 667. https://doi.org/10.1186/1471-2407-10-667
- Ng CS, Wood CG, Silverman PM, et al (2008). Renal cell carcinoma: diagnosis, staging, and surveillance. Am J Roentgenol, 191, 1220-32. https://doi.org/10.2214/AJR.07.3568
- Ozulker T, Ozulker F, Ozbek E, Ozpacaci T (2011). A prospective diag-nostic accuracy study of F-18 fluorodeoxyglucosepositron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun, 32, 265-72. https://doi.org/10.1097/MNM.0b013e3283442e3b
- Powles T, Ell PJ (2007). Does PET imaging have a role in renal cancers after all? Lancet Oncol, 8, 279-81. https://doi.org/10.1016/S1470-2045(07)70080-3
- Powles T, Murray I, Brock C, Oliver T, Avril N (2007). Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol, 51, 1511-20. https://doi.org/10.1016/j.eururo.2007.01.061
- Ramdave S, Thomas GW, Berlangieri SU, et al (2001). Clinical role of F-18 fluorodeoxyglucose positron emission tomography for de-tection and management of renal cell carcinoma. J Urol, 166, 825-30. https://doi.org/10.1016/S0022-5347(05)65845-4
- Sasaki R, Komaki R, Macapinlac H, et al (2005). [18F] fluorodeoxyglucose uptake by positron emission tomographypredicts outcome of non-small-cell lung cancer. J Clin Oncol, 23, 1136-43. https://doi.org/10.1200/JCO.2005.06.129
- Uzel EK, Ekmekcioglu O, Elicin O, Halac M, Uzel OE (2013). Is FDG -PET-CT a valuable tool in prediction of persistent disease in head and neck cancer. Asian Pac J Cancer Prev, 14, 4847-51. https://doi.org/10.7314/APJCP.2013.14.8.4847
- Wahl RL, Harney J, Hutchins G, Grossman HB (1991). Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18-F)-fluoro-Dglucose: pilot animal and human studies. J Urol, 146, 1470-4.
- Zhu SH, Zhang Y, Yu YH, et al (2013). FDG PET-CT in nonsmall cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential. Asian Pac J Cancer Prev, 14, 2925-9. https://doi.org/10.7314/APJCP.2013.14.5.2925
Cited by
- Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma vol.26, pp.6, 2016, https://doi.org/10.1007/s00330-015-4026-3
- 18F-FDG PET/CT in Bladder Cancer vol.41, pp.12, 2016, https://doi.org/10.1097/RLU.0000000000001403
- Evaluation of renal cell carcinoma histological subtype and fuhrman grade using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography vol.27, pp.11, 2017, https://doi.org/10.1007/s00330-017-4875-z
- Role of contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of renal tumors vol.39, pp.12, 2018, https://doi.org/10.1097/MNM.0000000000000915
- Sarcomatoid renal cell carcinoma: a case report and literature review vol.19, pp.1, 2018, https://doi.org/10.1186/s12882-018-0884-7